Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s earnings report is anticipated by WallStreet on May, 7, according to Faxor. EPS of $-0.58 is 13.73 % down from 2018’s $-0.51 EPS. Wall Street sees 34.88 % negative EPS growth as of May, 7. Ticker’s shares touched $16.86 during the last trading session after 1.00% change.Currently Intellia Therapeutics, Inc. is downtrending after 34.45% change in last April 16, 2018. NTLA has also 344,735 shares volume. NTLA underperformed the S&P500 by 38.82%.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.The firm is worth $763.02 million. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.Last it reported negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

For more Intellia Therapeutics, Inc. (NASDAQ:NTLA) news announced recently go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Intellia files $100M mixed shelf registration – Seeking Alpha” announced on October 12, 2018, “Long-Term Outlook For Intellia Therapeutics: October 9, 2018 – Seeking Alpha” on October 09, 2018, “The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% – Nasdaq” with a publish date: January 10, 2019, “Long-Term Outlook For Intellia – Seeking Alpha” and the last “Intellia Therapeutics to Present at October Healthcare Investor Conferences – GlobeNewswire” with publication date: September 24, 2018.